Evaluation of some biochemical markers as prognostic factors in malignant lymphomas.
This study aimed to estimate the pre- and post-treatment serum levels of glycosaminoglycans (GAGs), soluble p55 tumor necrosis factor receptor (sp55TNF-R) and soluble L-selectin in order to evaluate their prognostic significance and their role in monitoring tumor growth and host-tumor response in malignant lymphomas. Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage. For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital. Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV. In addition, 10 NHL patients were presented with B symptoms while, 21 did not. 7 apparently healthy individuals were selected as a control reference group.


RESULTS
1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control. Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction. 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL. 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity. 4- Elevated serum sp55TNF-R before treatment was associated with the presence of B symptoms and such association lead to a worse prognosis.


CONCLUSIONS
Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome. Serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
Salem
Hala A
HA
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Egypt.
Eissa
Laila A
LA
Rabbie
Ahmed M
AM
El-Helw
L M
LM
El-Gayar
Amal M
AM
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor; D001772:Blood Cell Count; D001799:Blood Sedimentation; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007677:Kidney Function Tests; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D019041:L-Selectin / Q000378:metabolism; D008111:Liver Function Tests; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000378:metabolism
D014408:Biomarkers, Tumor; D006025:Glycosaminoglycans; D047888:Receptors, Tumor Necrosis Factor, Type I; D019041:L-Selectin; D007770:L-Lactate Dehydrogenase